姚固秋,张禹,张羽坤,王磊

• 1:贵州航天医院心内科

摘要(Abstract)：

心律失常性心肌病是一种由持续或频繁发作的心律失常导致的可逆性左心室收缩功能障碍，其核心特征是在有效控制心律失常后，心功能可部分或完全恢复。随着对心力衰竭病因认识的深入，临床上越来越多地认识到心房颤动、频发室性期前收缩、心动过速等心律失常本身即可成为心肌病的直接病因。然而，心律失常性心肌病的诊断常具有延迟性，尤其是在以心力衰竭为首发表现的患者中，其潜在的可逆性病因易被忽视。本文报道1例青年男性患者，因持续性心房颤动合并严重左心室收缩功能下降，经导管射频消融术后心功能显著改善，最终修正诊断为心律失常性心肌病，并结合最新文献进行讨论。

关键词(KeyWords)： 心律失常性心肌病;心房颤动;导管射频消融术;心力衰竭

Abstract:

Keywords:

基金项目(Foundation): 遵义市科技计划项目[No：遵市科合HZ字（2024）133号]

作者(Author): 姚固秋,张禹,张羽坤,王磊

DOI: 10.13201/j.issn.1001-1439.2026.10.015

参考文献(References)：

• [1] Shoureshi P,Tan AY,Koneru J,et al.Arrhythmia-induced cardiomyopathy:JACC state-of-the-art review[J].J Am Coll Cardiol,2024,83(22):2214-2232.
• [2] Karakasis P,Theofilis P,Vlachakis PK,et al.Arrhythmia-induced cardiomyopathy in atrial fibrillation:pathogenesis,diagnosis,and treatment[J].Life(Basel),2025,15(11):1675.
• [3] Fabritz L,Hatem SN,Sossalla S.Arrhythmia-induced cardiomyopathy:focus on atrial fibrillation[J].Nat Rev Cardiol,2026,23(3):197-207.
• [4] Ahmad A,Mar PL,Olshansky B,et al.Echocardiographic changes and heart failure hospitalizations following rhythm control for arrhythmia-induced cardiomyopathy:results from a multicenter,retrospective study[J].J Interv Card Electrophysiol,2023,66(2):455-462.
• [5] Schach C,K??rtl T,Zeman F,et al.Clinical characterization of arrhythmia-induced cardiomyopathy in patients with tachyarrhythmia and idiopathic heart failure[J].JACC Clin Electrophysiol,2024,10(5):870-881.
• [6] Assaf A,Feng H,Bsoul M,et al.Characterization of arrhythmia-induced cardiomyopathy using magnetic resonance imaging in patients with persistent atrial fibrillation and left ventricular systolic dysfunction-insights from DECAAF II[J].Eur J Heart Fail,2025,27(9):1622-1632.
• [7] Bachani N,Shah H,Bansal R,et al.Characterization of myocardial recovery in patients with tachycardiomyopathy[J].Pacing Clinical Electrophis,2025,48(3):329-333.
• [8] Báez Cabanillas MV,Heidenreich PA.Emerging concepts in heart failure management and treatment:focus on tachycardia-induced cardiomyopathy[J].Drugs Context,2023,12:2022-8-4.
• [9] Desai D,Maheta DK,Agrawal SP,et al.Understanding arrhythmia-induced cardiomyopathy:symptoms and treatments[J].Cardiol Rev,2024 Jul 18.doi:10.1097/CRD.0000000000000755.
• [10] Porcari A,de Luca A,Grigoratos C,et al.Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization:disclosing the arrhythmic substrate within the heart muscle[J].Heart Fail Rev,2022,27(1):49-69.
• [11] Wani SA,Naveed MA,Saeed A,et al.Updated meta-analysis of catheter ablation versus medical therapy in atrial fibrillation with heart failure with preserved ejection fraction[J].J Arrhythm,2025,41(6):e70236.
• [12] Packer DL,Piccini JP,Monahan KH,et al.Ablation versus drug therapy for atrial fibrillation in heart failure:results from the CABANA trial[J].Circulation,2021,143(14):1377-1390.
• [13] Song ZL,Wang SY,Qidong Z,et al.Catheter ablation versus medical rate control for persistent atrial fibrillation in older heart failure patients with reduced ejection fraction[J].Heart,2025,111(17):811-817.
• [14] Khiabani AJ,Schuessler RB,Damiano RJ.Surgical ablation of atrial fibrillation in patients with heart failure[J].J Thorac Cardiovasc Surg,2021,162(4):1100-1105.
• [15] Yehya A,Batista JL,Sauer AJ,et al.Revisiting ICD therapy for primary prevention in patients with heart failure and reduced ejection fraction[J].JACC Heart Fail,2025,13(1):1-13.
• [16] Deering TF,Reiffel JA,Solomon AJ,et al.Chapter 2:rate versus rhythm control[J].Am J Cardiol,2023,205:S7-S9.
• [17] Al-Aidarous S,Rajappan S,Ahluwalia N,et al.Withdrawing guideline-directed medical therapy after left ventricular ejection fraction recovery following atrial fibrillation ablation:a multicentre cohort study[J].Open Heart,2025,12(2):e003733.
• [18] Domínguez-Rodríguez LM,Dobarro D,Iglesias-Otero C,et al.Guideline-directed medical therapy for heart failure in arrhythmia-induced cardiomyopathy with improved left ventricular ejection fraction[J].Eur J Heart Fail,2025,27(3):442-452.
• [19] Schach C,Lavall D,Vo??hage N,et al.Time to recovery from systolic dysfunction correlates with left ventricular fibrosis in arrhythmia-induced cardiomyopathy[J].Life,2024,14(3):330.
• [20] McDonagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3599-3726.
• [21] Heidenreich PA,Bozkurt B,Aguilar D,et al.2022 AHA/ACC/HFSA guideline for the management of heart failure[J].J Am Coll Cardiol,2022,79(17):e263-e421.
• [22] Daoud EG.Patch wearable defibrillator excellent therapy,but patient acceptance is a sticky issue[J].J Am Coll Cardiol,2024,84(6):537-539.
• [23] 袁璟，廖梦阳，程翔，等.心力衰竭常见病因及合并症的基层处理专家建议[J].临床心血管病杂志，2024,40(3):161-166.